269 related articles for article (PubMed ID: 10534061)
21. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
[TBL] [Abstract][Full Text] [Related]
22. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
Lee JH; Choi SJ; Lee JH; Kim SE; Park CJ; Chi HS; Lee MS; Lee JS; Kim WK; Lee KH
Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
[TBL] [Abstract][Full Text] [Related]
23. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Bognàr T; Bartelink IH; Egberts TCG; Rademaker CMA; Versluys AB; Slatter MA; Kletzel M; Nath CE; Cuvelier GDE; Savic RM; Dvorak C; Long-Boyle JR; Cowan MJ; Bittencourt H; Bredius RGM; Güngör T; Shaw PJ; Ansari M; Hassan M; Krajinovic M; Hempel G; Marktel S; Chiesa R; Théoret Y; Lund T; Orchard PJ; Wynn RF; Boelens JJ; Lalmohamed A
Transplant Cell Ther; 2022 Apr; 28(4):196-202. PubMed ID: 35065280
[TBL] [Abstract][Full Text] [Related]
24. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
Roeker LE; Kim HT; Glotzbecker B; Nageshwar P; Nikiforow S; Koreth J; Armand P; Cutler C; Alyea EP; Antin JH; Richardson PG; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2019 Jan; 25(1):137-144. PubMed ID: 30081073
[TBL] [Abstract][Full Text] [Related]
25. High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma.
Hwang DY; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Yang WI; Kim JS
Leuk Lymphoma; 2016; 57(1):51-7. PubMed ID: 25899401
[TBL] [Abstract][Full Text] [Related]
26. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma.
Bains T; Chen AI; Lemieux A; Hayes-Lattin BM; Leis JF; Dibb W; Maziarz RT
Leuk Lymphoma; 2014 Mar; 55(3):583-7. PubMed ID: 23697844
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
[TBL] [Abstract][Full Text] [Related]
28. Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation.
Salman B; Al-Khabori M; Al-Huneini M; Al-Rawas A; Dennison D; Al-Za'abi M
Int J Hematol; 2020 Aug; 112(2):210-216. PubMed ID: 32468179
[TBL] [Abstract][Full Text] [Related]
29. [Hematopoietic stem cell transplantation with busulfanthiotepa-cyclophosphamide conditioning for pediatric patients with high-risk acute lymphoblastic leukemia].
Umeda K; Lin YW; Watanabe K; Adachi S; Usami I; Akiyama Y; Kubota M; Nakahata T
Rinsho Ketsueki; 2001 Sep; 42(9):685-90. PubMed ID: 11680979
[TBL] [Abstract][Full Text] [Related]
30. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
Diaz MA; Vicent MG; Madero L
Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802
[TBL] [Abstract][Full Text] [Related]
31. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
Kalayoglu-Besisik S; Yenerel MN; Caliskan Y; Ozturk S; Besisik F; Sargin D
Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
[TBL] [Abstract][Full Text] [Related]
32. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
[TBL] [Abstract][Full Text] [Related]
33. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
34. Toxicity of tandem high-dose chemotherapy and autologous stem cell transplantation using carboplatin-thiotepa-etoposide and cyclophosphamide-melphalan regimens for malignant brain tumors in children and young adults.
Lee SH; Son MH; Sung KW; Choi YB; Lee NH; Yoo KH; Koo HH; Lim DH; Shin HJ
J Neurooncol; 2014 Dec; 120(3):507-13. PubMed ID: 25108776
[TBL] [Abstract][Full Text] [Related]
35. The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan.
Lee CC; Chang HH; Lu MY; Yang YL; Chou SW; Lin DT; Jou ST; Yao M; Li CC; Yeh SP; Chen MH; Gau JP; Li SS; Wang PN; Liu YC; Wang TF; Tan TD; Lee MY; Yu MS; Wang CC; Lin SC; Chen YC; Su YC; Su KY; Lin KH
Ann Hematol; 2019 Mar; 98(3):745-752. PubMed ID: 30666432
[TBL] [Abstract][Full Text] [Related]
36. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.
Gutierrez-Delgado F; Holmberg L; Hooper H; Petersdorf S; Press O; Maziarz R; Maloney D; Chauncey T; Appelbaum F; Bensinger W
Bone Marrow Transplant; 2003 Aug; 32(3):279-85. PubMed ID: 12858199
[TBL] [Abstract][Full Text] [Related]
37. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen.
Brodsky R; Topolsky D; Crilley P; Bulova S; Brodsky I
Am J Clin Oncol; 1990 Jun; 13(3):221-5. PubMed ID: 2346127
[TBL] [Abstract][Full Text] [Related]
38. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
Hara J; Osugi Y; Ohta H; Matsuda Y; Nakanishi K; Takai K; Fujisaki H; Tokimasa S; Fukuzawa M; Okada A; Okada S
Bone Marrow Transplant; 1998 Jul; 22(1):7-12. PubMed ID: 9678789
[TBL] [Abstract][Full Text] [Related]
39. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT.
Cantoni N; Gerull S; Heim D; Halter J; Bucher C; Buser A; Tsakiris DA; Passweg J; Tichelli A; Stern M; Gratwohl A
Bone Marrow Transplant; 2011 Mar; 46(3):344-9. PubMed ID: 20548339
[TBL] [Abstract][Full Text] [Related]
40. Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning.
Terakura S; Onizuka M; Fukumoto M; Kuwatsuka Y; Kohno A; Ozawa Y; Miyamura K; Inagaki Y; Sawa M; Atsuta Y; Suzuki R; Naoe T; Morishita Y; Murata M;
Int J Hematol; 2020 Jan; 111(1):84-92. PubMed ID: 31555969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
